Editas Medicine
EDIT
197 hedge funds and large institutions have $1.03B invested in Editas Medicine in 2018 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 69 increasing their positions, 30 reducing their positions, and 16 closing their positions.
294% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 16
130% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 30
36% more call options, than puts
Call options by funds: $47.9M | Put options by funds: $35.4M
30% more funds holding
Funds holding: 151 → 197 (+46)
11% more capital invested
Capital invested by funds: $934M → $1.03B (+$98.3M)
2.54% less ownership
Funds ownership: 68.97% → 66.44% (-2.5%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$44.9M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$18.1M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$14.8M |
| 4 |
Chevy Chase Trust
Bethesda,
Maryland
|
+$14M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$51.5M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$27.8M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$24M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.7M |
| 5 |
DM
Deerfield Management
New York
|
-$19.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GTC
201
Ghost Tree Capital
New York
| – | -$2M | -65,000 | Closed |
|
|
KJHP
202
K.J. Harrison & Partners
Toronto,
Ontario, Canada
| – | -$492K | -16,020 | Closed |
|
203
Group One Trading
Chicago,
Illinois
| – | -$435K | -12,196 | Closed |
|
|
FAIM
204
Financial Advocates Investment Management
Olympia,
Washington
| – | -$319K | -10,700 | Closed |
|
205
Teacher Retirement System of Texas
Austin,
Texas
| – | -$253K | -8,240 | Closed |
|
|
PL
206
Plancorp LLC
Saint Louis,
Missouri
| – | -$235K | -7,649 | Closed |
|
207
Parallax Volatility Advisers
San Francisco,
California
| – | -$159K | -5,166 | Closed |
|
208
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$80K | -2,600 | Closed |
|
209
Pacer Advisors
Malvern,
Pennsylvania
| – | -$56K | -1,825 | Closed |
|
|
KJWM
210
Kiley Juergens Wealth Management
Olympia,
Washington
| – | -$15K | -500 | Closed |
|
|
DCM
211
Delpha Capital Management
New York
| – | -$10K | -319 | Closed |
|
EDIT Hedge Fund Activity: Q1 2018 in Review
197 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2018, worth a combined $1.03B — up 11% from $934M a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new EDIT positions and 16 closed out — a net gain of 47 holders — while 69 added to existing stakes and 30 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $44.9M. The largest seller was Flagship Pioneering, exiting entirely with an estimated $51.5M sold.
- 197 institutional investors held Editas Medicine (EDIT) as of Q1 2018, up from 151 in Q4 2017.
- Funds reported $1.03B of Editas Medicine stock for Q1 2018, up 11% quarter-over-quarter.
- 63 funds opened new Editas Medicine positions in Q1 2018 and 16 closed out, a net change of +47 holders.
- The largest Editas Medicine buyer in Q1 2018 was Morgan Stanley, an estimated $44.9M added.
- The largest Editas Medicine seller in Q1 2018 was Flagship Pioneering, an estimated $51.5M sold.
Based on aggregated 13F filings for Q1 2018.